Diagnostic Microbiology & Infectious Disease
Volume 62, Issue 4 , Pages 460-463 , December 2008

Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent

  • Helio S. Sader

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-665-3370x200; fax: +1-319-655-3371.
    • ,
  • Laura M. Koeth

      Affiliations

    • Laboratory Specialists, Inc, Westlake, OH 44145, USA
    • ,
  • James A. Poupard

      Affiliations

    • Pharma Institute of Philadelphia, PA 19129, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA

Received 29 July 2008 ,Accepted 27 August 2008.

References 

  1. Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 2007;51:198–207
  2. Andriole VT. The quinolones: past, present, and future. Clin. Infect. Dis. 2005;41(Suppl 2):S113–S119
  3. Barry AL, Jones RN. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J. Clin. Microbiol. 1987;25:1570–1571
  4. Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. 7th ed.. Wayne, PA: CLSI; 2006;
  5. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18. Wayne, PA: CLSI; 2008;
  6. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 2005;41:118–121
  7. Jones RN, Pfaller MA. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997–99). Diagn. Microbiol. Infect. Dis. 2001;39:237–243
  8. Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 2006;44:2622–2625
  9. Moellering JRC. The fluoroquinolones: the last samurai?. Clin. Infect. Dis. 2005;41(Suppl 2):S111
  10. National Committee for clinical and Laboratory Standards . Development of in vitro susceptibility testing criteria and quality controls parameters; approved guideline, second edition, M23-A2. Wayne, PA: NCCLS; 2001;
  11. Schito AM, Schito GC. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa. J. Chemother. 2004;16(Suppl. 2):3–7
  12. Schurek KN, Adam HJ, Hoban DJ, Zhanel GG. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Int. J. Antimicrob. Agents. 2006;28:266–269
  13. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs. 2007;67:2355–2382

☆ Since the completion of this manuscript, the Clinical and Laboratory Standards Institute [CLSI (2009, in press) Performance standards for antimicrobial susceptibility testing; 19th informational supplement, M100-S19. CLSI, Wayne, PA] has approved and published these recommendations.

PII: S0732-8893(08)00396-9

doi: 10.1016/j.diagmicrobio.2008.08.020

Diagnostic Microbiology & Infectious Disease
Volume 62, Issue 4 , Pages 460-463 , December 2008

Article Tools

* Image Usage & Resolution